TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 46nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 67nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 74nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 159nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 180nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 274nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 380nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 390nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 550nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson And Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair